TECHNOLOGY REVIEW, MIT’S MAGAZINE OF INNOVATION, NAMES COLIN HILL ONE OF THE WORLD’S TOP YOUNG INNOVATORS
| Contact: |  |
Debbie Pfeifer Gene Network Sciences (206) 282-5098 debbie@gnsbiotech.com |
- Gene Network Sciences CEO Also Wins Black Enterprise’s Rising Star Award -
ITHACA, NY - September 20, 2004 - Gene Network Sciences (GNS), a leader in systems biology, today announced that its CEO and co-founder, Colin Hill, has been named to the 2004 list of the world’s 100 Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Hill was also named as the winner of Black Enterprise’s Rising Star Award, which recognizes an individual under the age of 35 whose outstanding skills, professionalism, and perseverance have established him as a future business leader. Profiles of Hill and GNS will appear in the October issue of both magazines.
Using biological and chemical data, GNS creates robust computer models of cell function and human biology. The company’s data-driven simulations of cancer cells and the heart significantly accelerate drug development by reducing clinical trial failures. Hill develops the strategic roadmap and vision for GNS, and brings to his role years of hands-on scientific experience and expertise in computational physics and systems biology.
The Technology Review 100
The TR100, chosen by the editors of Technology Review and an elite panel of judges, consists of 100 individuals under age 35 whose innovative work in technology has a profound impact on today’s world. This year’s nominees are recognized for their contributions in transforming the nature of technology and business in industries such as biotechnology and medicine, computing, and nanotechnology.
The 2004 TR100’s unparalleled panel of judges includes senior executives from the following organizations: Boston University, Caltech, Cambridge University, CombinatoRx, Concept2Company, Cornell University, General Electric, Geekcorps, Georgia Tech, Harvard Medical School, Hewlett-Packard, IBM, Intellectual Ventures, Microsoft, MIT, Northwestern University, PureTech Ventures, Singapore Institute of Bioengineering and Nanotechnology, TIAX, Wharton, Xerox, and YankeeTek Ventures.
“In the five years since we began naming our annual selection of the world’s top innovators under age 35, inclusion among the TR100 has become one of the most prestigious awards for young innovators around the world,” said David Rotman, executive editor of Technology Review. “This year’s winners are all pioneering fascinating innovations in the fields of biomedicine, computing and nanotechnology, and were chosen after a rigorous selection and judging process. The result is an elite group whose visions and inventions will shape the future of technology.”
Hill will be honored September 29 - 30 at Technology Review’s Emerging Technologies Conference at MIT. The event features keynotes, panels and breakout discussions on the transformative technological innovations that have the potential to fuel new economic growth and dramatically change the future. Keynote speakers include Vinod Khosla, founding CEO of Sun Microsystems and General Partner at Kleiner, Perkins, Caufield & Byers; Ray Kurzweil, renowned inventor, author and founder of Kurzweil Technologies; and Rick Wagoner, chairman of General Motors. More information on ETC2004 can be found at www.tretc.com.
About Technology Review, Inc.
Technology Review, Inc., an MIT Enterprise, delivers essential information about emerging technologies and their impact on business leaders. Since 1998, paid circulation for the company’s magazine, Technology Review, has more than tripled, climbing from 92,000 to 315,000. Combined with its signature events, newsletters, and online businesses, Technology Review reaches over two million business leaders throughout the world each month.
About Gene Network Sciences
Founded in August 2000, Gene Network Sciences (www.gnsbiotech.com) is a privately held biotech company headquartered in Ithaca, New York. A pioneer in the field of systems biology, GNS integrates biological and chemical data to create accurate and robust computer models of cell function and human biology. GNS helps pharmaceutical companies better understand the complex human biological systems that they seek to affect. The company’s technology will ultimately increase clinical trial success rates and help bring better drugs to market faster.